Skip to main content

For US Healthcare Professionals only

Graphic showing the Thymoglobulin® [Anti‑thymocyte Globulin (Rabbit)] and a large ‘25+ YEARS commitment in the field of kidney transplant’ graphic on the right, displayed on a teal background with subtle curved line patterns.

Celebrating Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)] and 25+ Years of Kidney Transplant Evolution

Pioneering Spirits: 20+ Years in Transplant

Watch transplant leaders share experiences and insights on the evolution of kidney transplantation.

The field of kidney transplantation has continued to evolve thanks largely due to the pioneering spirit of many healthcare professionals. In recognition of this commitment, we are excited to share Pioneering Spirits: 20+ Years in Transplant. Told from the perspective of transplant leaders, this short film highlights the history and evolution of the field over the last 20+ years.

Click here for full Prescribing Information.

Special Thanks

We appreciate those who made this film possible and for their dedication to the field of kidney transplantation.

  • Yolanda Becker MD
  • Kenneth Chavin MD, PhD
  • Matthew Cooper MD
  • Richard Formica MD
  • John Freidewald MD
  • A. Osama Gaber MD, FACS
  • Mark A. Hardy MD
  • Allan Kirk MD, PhD
  • Jon Kobashigawa MD
  • Mark A. Hardy MD
  • Allan Kirk MD, PhD
  • Jon Kobashigawa MD
  • Mark Laftavi MD
  • Alan Langnas DO, FACS
  • Angela Maldonado Pharm.D
  • Cosme Manzarbeitia MD
  • Christopher Marsh MD
  • Michael R. Marvin MD
  • Thomas McCune MD
  • Joseph Keith Melancon MD
  • Joshua Miller MD
  • Robert Montgomery MD
  • David Mulligan MD, FACS
  • Kenneth Newell MD, PhD
  • Lloyd E. Ratner MD, MPH, FACS
  • Jesse Schold PhD
  • Dorry Segev MD, PhD
  • David Taber Pharm.D
  • Flavio Vincenti MD
  • Jason Wellen MD, MBA

PREVIOUS
← Dosing & Administration: Treatment Considerations

Important Safety Information

WARNING: IMMUNOSUPPRESSION. Thymoglobulin should only be used by physicians experienced in immunosuppressive therapy in transplantation.
  • Contraindications. Thymoglobulin is contraindicated in patients with a history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have active acute or chronic infections which contraindicate any additional immunosuppression.
  • Management of Immunosuppression. To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of Thymoglobulin use. Dosing for Thymoglobulin is different from dosing for other ATG products, because protein composition and concentrations vary depending on the source of ATG. Thymoglobulin should be used under strict medical supervision in a hospital setting, and patients should be carefully monitored during the infusion.
  • Immune Mediated Reactions. Serious immune-mediated reactions, including anaphylaxis or severe cytokine release syndrome (CRS), have been reported with the use of Thymoglobulin. Fatal anaphylaxis has been reported. If an anaphylactic reaction occurs, the infusion should be terminated immediately.
  • Infusion-Associated Reactions. Cases consistent with cytokine release syndrome (CRS) have been reported with rapid infusion rates. CRS is attributed to the release of cytokines by activated monocytes and lymphocytes. Severe acute CRS can cause serious cardiorespiratory events and/or death. Close compliance with the recommended dosage and infusion time may reduce the incidence and severity of infusion-associated reactions (IARs). Slowing the infusion rate may minimize many of these IARs. Reactions at the infusion site may include pain, swelling, and redness of the skin.
  • Hematologic Effects. Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments. Total white blood cell and platelet counts should be monitored.
  • Infection and Malignancy. Infections, reactivation of infection, febrile neutropenia, sepsis, malignancies including lymphoproliferative disorders (LPD) and other lymphomas as well as solid tumors have been reported after Thymoglobulin administration in combination with multiple immunosuppressive agents. These events can be fatal.
  • Immunization. The safety of immunization with attenuated live vaccines following Thymoglobulin therapy has not been studied; therefore, immunization with attenuated live vaccines is not recommended for patients who have recently received Thymoglobulin.
  • Overdosage. Thymoglobulin overdosage may result in leukopenia (including lymphopenia and neutropenia) and/ or thrombocytopenia, which can be managed with dose reduction.
  • Adverse Reactions. The most common adverse reactions and laboratory abnormalities (incidence >5% higher than comparator) are urinary tract infection, abdominal pain, hypertension, nausea, shortness of breath, fever, headache, anxiety, chills, increased potassium levels in the blood, and low counts of platelets and white blood cells.
  • During post-marketing surveillance, arthralgia/myalgia, lymphadenopathy, proteinuria, and decreased oxygen saturation tend to occur 5 to 15 days after Thymoglobulin infusion and are consistent with serum sickness. Symptoms are manageable with corticosteroid treatment.

Click here for full Prescribing Information including Boxed WARNING.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Important Safety Information

*Approved for treatment of acute rejection in patients receiving a kidney transplant, 1998. Approved for prophylaxis of acute rejection in patients receiving a kidney transplant, 2017. Thymoglobulin is to be used in conjunction with concomitant immunosuppression.1,2

References:

1. Thymoglobulin [prescribing information]. Cambridge, MA: Genzyme Corporation; 2026.
2. Data on file. Sanofi.

Thymoglobulin and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2600049-v1.0-03/2026

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContactAccessibility Statement
© 2026 Sanofi. All rights reserved.